Patent · US Expired

Therapeutic method for reducing angiogenesis

US7740841B1 · kind B1 · utility

0Cited by
46References
5Claims
0Family size

Assignee

Inventor

Key dates

Filing dateMar 31, 2000
Grant dateJun 22, 2010
Priority date
Expiry dateMar 31, 2020

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2039/505
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method of controlling or treating an angiogenic dependent condition in a mammal, preferably in a human by administering an anti-angiogenic molecule such as an angiogenesis growth factor antagonist, and a chemotherapeutic agent in amounts and frequencies effective, in combination, to produce a regression or arrest of said condition while minimizing or preventing significant toxicity of the chemotherapeutic agent. Also a kit for controlling or treating an angiogenic dependent condition in a mammal, preferably in a human, comprising an anti-angiogenic molecule, such as an angiogenesis growth factor antagonist, and a chemotherapeutic agent in amounts effective, in combination, to produce a regression or arrest of said condition while minimizing or preventing significant toxicity of the chemotherapeutic agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.